Research resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant

Molecular Endocrinology

Volumn 28, Issue 12, 2014, Pages 2072-2081

  Li, Yin ^a   Arao, Yukitomo ^a   Hall, Julie M ^b   Burkett, Sandra ^c   Liu, Liwen ^a   Gerrish, Kevin ^a   Cavailles, Vincent ^d   Korach, Kenneth S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b CAMPBELL UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN; ESTROGEN RECEPTOR;

ARTICLE; CELL TYPE; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; ESTROGEN ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MICROARRAY ANALYSIS; OVARIAN CANCER CELL LINE; REPORTER GENE; SHORT TANDEM REPEAT; GENE TRANSLOCATION; GENETICS; OVARY TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA; FEMALE; GENOTYPE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; TRANSLOCATION, GENETIC;

EID: 84914110958     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1229     Document Type: Article

References (48)

1. Simpkins F, Garcia-Soto A, Slingerland J. New insights on the role of hormonal therapy in ovarian cancer. Steroids. 2013;78:530-537.
2. McGuire WP 3rd, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer. 2003;89(suppl 3): S3-S8.
3. Badia E, Docquier A, Busson M, et al. Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells. J Steroid Biochem Mol Biol. 2012; 132:176-185.
4. Korch C, Spillman MA, Jackson TA, et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol. 2012;127:241-248.
5. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA. 1993;90:11162-11166.
6. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296:1642-1644.
7. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81:1535-1565.
8. Pettersson K, Gustafsson JA. Role of estrogen receptor β in estrogen action. Annu Rev Physiol. 2001;63:165-192.
9. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv. 2005;5: 343-357.
10. O’Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004;18:1859-1875.
11. Drummond AE, Fuller PJ. The importance of ERβ signalling in the ovary. J Endocrinol. 2010;205:15-23.
12. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor α (ER-α) and β (ER-β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-β in neoplastic tissues. J Clin Endocrinol Metab. 1998;83:1025-1028.
13. Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor-α and -β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res. 1998;58:5367-5373.
14. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A, Mor G. Absence of estrogen receptor-β expression in metastatic ovarian cancer. Obstet Gynecol. 2000;96:417-421.
15. Docquier A, Garcia A, Savatier J, et al. Negative regulation of estrogen signaling by ERβ and RIP140 in ovarian cancer cells. Mol Endocrinol. 2013;27:1429-1441.
16. Roger P, Pujol P, Lucas A, Baldet P, Rochefort H. Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. Am J Pathol. 1998;153:1579-1588.
17. Moll F, Katsaros D, Lazennec G, et al. Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene. 2002;21:1097-1107.
18. Henley DV, Mueller S, Korach KS. The short-chain fatty acid methoxyacetic acid disrupts endogenous estrogen receptor-α-mediated signaling. Environ Health Perspect. 2009;117:1702-1706.
19. Reid G, Metivier R, Lin CY, et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor α, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene. 2005;24:4894-4907.
20. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME. GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat. 2005;92:141-149.
21. Berry M, Nunez AM, Chambon P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA. 1989;86:1218-1222.
22. Katzenellenbogen BS. Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways. J Soc Gynecol Investig. 2000;7:S33-S37.
23. Rio MC, Bellocq JP, Daniel JY, et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science. 1988;241:705-708.
24. Geisinger KR, Kute TE, Pettenati MJ, et al. Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer. 1989;63:280-288.
25. Bardin A, Moll F, Margueron R, et al. Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology. 2005;146:760-768.
26. Hayashido Y, Lucas A, Rougeot C, Godyna S, Argraves WS, Rochefort H. Estradiol and fibulin-1 inhibit motility of human ovarianand breast-cancer cells induced by fibronectin. Int J Cancer. 1998; 75:654-658.
27. Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab. 1992;75:1497-1502.
28. Moll F, Millet C, Noel D, et al. Chordin is underexpressed in ovarian tumors and reduces tumor cell motility. FASEB J. 2006;20: 240-250.
29. Cunat S, Rabenoelina F, Daures JP, et al. Aromatase expression in ovarian epithelial cancers. J Steroid Biochem Mol Biol. 2005;93: 15-24.
30. Annab LA, Hawkins RE, Solomon G, Barrett JC, Afshari CA. Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line. Breast Cancer Res. 2000;2:139-148.
31. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol. 2003;17:792-803.
32. Baldwin WS, Travlos GS, Risinger JI, Barrett JC. Melatonin does not inhibit estradiol-stimulated proliferation in MCF-7 and BG-1 cells. Carcinogenesis. 1998;19:1895-1900.
33. Crawford MH, Beaty KG. DNA fingerprinting in anthropological genetics: past, present, future. Investig Genet. 2013;4:23.
34. Hall JM, McDonnell DP, Korach KS. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol. 2002;16: 469-486.
35. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 1982;10:7895-7903.
36. Tremblay GB, Tremblay A, Copeland NG, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β. Mol Endocrinol. 1997;11:353-365.
37. Schrock E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science. 1996;273:494-497.
38. Wang S, Aarts JM, Evers NM, Peijnenburg AA, Rietjens IM, Bovee TF. Proliferation assays for estrogenicity testing with high predictive value for the in vivo uterotrophic effect. J Steroid Biochem Mol Biol. 2012;128:98-106.
39. Kang NH, Hwang KA, Kim TH, Hyun SH, Jeung EB, Choi KC. Induced growth of BG-1 ovarian cancer cells by 17β-estradiol or various endocrine disrupting chemicals was reversed by resveratrol via downregulation of cell cycle progression. Mol Med Rep. 2012; 6:151-156.
40. Hall JM, Korach KS. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis. Mol Carcinog. 2013;52:715-725.
41. American Type Culture Collection Standards Development Organization Work Group ASN-0002. Cell line misidentification: the beginning of the end. Nat Rev Cancer. 2010;10:441-448.
42. Masters JR, Thomson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA. 2001;98:8012-8017.
43. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology. 1997;138: 4613-4621.
44. Couse JF, Yates MM, Deroo BJ, Korach KS. Estrogen receptor-β is critical to granulosa cell differentiation and the ovulatory response to gonadotropins. Endocrinology. 2005;146:3247-3262.
45. Greene LM, Twal WO, Duffy MJ, et al. Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer. 2003;88:871-878.
46. Clinton GM, Rougeot C, Derancourt J, et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci USA. 1996;93: 316-320.
47. Rondon-Lagos M, Verdun Di Cantogno L, Marchio C, et al. Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. Mol Cytogenet. 2014;7:8.
48. Bahia H, Ashman JN, Cawkwell L, et al. Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization. Int J Oncol. 2002;20:489-494.